@article{1fc1888ed6044f1a9a35e5d4696383c4,
title = "Lineage regulators direct BMP and Wnt pathways to cell-specific programs during differentiation and regeneration",
abstract = "BMP and Wnt signaling pathways control essential cellular responses through activation of the transcription factors SMAD (BMP) and TCF (Wnt). Here, we show that regeneration of hematopoietic lineages following acute injury depends on the activation of each of these signaling pathways to induce expression of key blood genes. Both SMAD1 and TCF7L2 co-occupy sites with master regulators adjacent to hematopoietic genes. In addition, both SMAD1 and TCF7L2 follow the binding of the predominant lineage regulator during differentiation from multipotent hematopoietic progenitor cells to erythroid cells. Furthermore, induction of the myeloid lineage regulator C/EBPα in erythroid cells shifts binding of SMAD1 to sites newly occupied by C/EBPα, whereas expression of the erythroid regulator GATA1 directs SMAD1 loss on nonerythroid targets. We conclude that the regenerative response mediated by BMP and Wnt signaling pathways is coupled with the lineage master regulators to control the gene programs defining cellular identity.",
author = "Eirini Trompouki and Bowman, {Teresa V.} and Lawton, {Lee N.} and Fan, {Zi Peng} and Wu, {Dai Chen} and Anthony Dibiase and Martin, {Corey S.} and Cech, {Jennifer N.} and Sessa, {Anna K.} and Leblanc, {Jocelyn L.} and Pulin Li and Durand, {Ellen M.} and Christian Mosimann and Heffner, {Garrett C.} and Daley, {George Q.} and Paulson, {Robert F.} and Young, {Richard A.} and Zon, {Leonard I.}",
note = "Funding Information: We would like to acknowledge A. Mullen and D. Orlando for helpful discussions and sharing critical insights prior to publication and G. Frampton for analytical advice and development of the ChIP-seq analysis platform. We thank F. Rentzsch and M. Hammerschmidt for the Hs:BMP zebrafish line, J. Tucker and M. Mullins for the Hs:Chordin zebrafish line, and T. Schlaeger for the GATA2 expression plasmid. We are grateful to X. Bai and R. White for critical reviews of the manuscript and O. Tamplin for computational advice. The Whitehead Genome Technology Core was instrumental in timely data production and analysis support, especially S. Gupta. Microarray studies were performed by the Molecular Genetics Core Facility at Children's Hospital Boston, supported by NIH-P50-NS40828 and NIH-P30-HD18655. This work was supported by NIH #5PO1HL32262-29 and #5R01HL048801-18 (to L.I.Z), NIH 1R01DK080040-01 (to R.F.P.), R01-HG002668 (to R.A.Y.), NIH K01 DK085270-02 (to T.V.B.), NIH U01 HL100001, NIH 1 RC2HL102815, and ROFAR (to G.Q.D.), NIH T32HL007623 (to G.C.H.), HHMI (to L.I.Z. and G.Q.D.), and EMBO fellowship and Jane Coffin Childs Memorial Fund (to E.T.). L.I.Z. is a founder and stock holder of Fate, Inc. and a scientific advisor for Stemgent. G.Q.D. is a member of the Scientific Advisory Boards of MPM Capital, Inc., Epizyme, Inc., and iPierian, Inc. ",
year = "2011",
month = oct,
day = "28",
doi = "10.1016/j.cell.2011.09.044",
language = "English (US)",
volume = "147",
pages = "577--589",
journal = "Cell",
issn = "0092-8674",
publisher = "Cell Press",
number = "3",
}